|
131 |
Kein Nachteil durch Wechsel zwischen Biosimilar und Originator
Enthalten in Hautnah / Dermatologie Bd. 34, 12.5.2018, Nr. 3, date:5.2018: 28-29
|
|
|
|
132 |
Label discrepancies between originator and generic drugs impact safety
Enthalten in Reactions weekly Bd. 1802, 2.5.2020, Nr. 1, date:5.2020: 8
|
|
|
|
133 |
Non-medical Switching from Originator Tumor Necrosis Factor Inhibitors to Their Biosimilars: Systematic Review of Randomized Controlled Trials and Real-World Studies
Enthalten in Advances in therapy Bd. 35, 6.8.2018, Nr. 9, date:9.2018: 1295-1332
|
|
|
|
134 |
Non-pharmacological Effects in Switching Medication: The Nocebo Effect in Switching from Originator to Biosimilar Agent
Enthalten in BioDrugs Bd. 32, 29.9.2018, Nr. 5, date:10.2018: 397-404
|
|
|
|
135 |
Originator-to-biosimilar non-medical switch may not yield such great cost savings
Enthalten in PharmacoEconomics & outcomes news Bd. 892, 27.11.2021, Nr. 1, date:11.2021: 17
|
|
|
|
136 |
Outcomes Following Adalimumab Bio-originator to Biosimilar Switch—A Comparison Using Real-world Patient- and Physician-Reported Data in European Countries
Enthalten in Rheumatology and therapy Bd. 10, 12.1.2023, Nr. 2, date:4.2023: 433-445
|
|
|
|
137 |
Perception of Originator Biologics and Biosimilars: A Survey Among Belgian Rheumatoid Arthritis Patients and Rheumatologists
Enthalten in BioDrugs Bd. 31, 19.9.2017, Nr. 5, date:10.2017: 447-459
|
|
|
|
138 |
Physicochemical and Functional Comparability Between the Proposed Biosimilar Rituximab GP2013 and Originator Rituximab
Enthalten in BioDrugs Bd. 27, 7.5.2013, Nr. 5, date:10.2013: 495-507
|
|
|
|
139 |
Rapid monitoring of health services use following a policy to switch patients from originator to biosimilar etanercept—a cohort study in British Columbia
Enthalten in BMC Rheumatology Bd. 6, 27.1.2022, Nr. 1, date:12.2022: 1-9
|
|
|
|
140 |
Safety evaluation of infliximab originator and biosimilars
Enthalten in Reactions weekly Bd. 1727, 10.11.2018, Nr. 1, date:11.2018: 11
|
|
Administration
